+

WO1999067201A1 - Derives d'acide hydroxamique comme inhibiteurs de la production de la proteine humaine cd23 et de la liberation du facteur de necrose des tumeurs (tnf) - Google Patents

Derives d'acide hydroxamique comme inhibiteurs de la production de la proteine humaine cd23 et de la liberation du facteur de necrose des tumeurs (tnf) Download PDF

Info

Publication number
WO1999067201A1
WO1999067201A1 PCT/GB1999/001954 GB9901954W WO9967201A1 WO 1999067201 A1 WO1999067201 A1 WO 1999067201A1 GB 9901954 W GB9901954 W GB 9901954W WO 9967201 A1 WO9967201 A1 WO 9967201A1
Authority
WO
WIPO (PCT)
Prior art keywords
tert
naphthylmethyl
succinyl
nmr
dmso
Prior art date
Application number
PCT/GB1999/001954
Other languages
English (en)
Inventor
Andrew Faller
David Timothy Macpherson
Peter Henry Milner
Jayshree Mistry
John Gerard Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ508229A priority Critical patent/NZ508229A/en
Priority to US09/701,946 priority patent/US6458779B1/en
Priority to SK1956-2000A priority patent/SK19562000A3/sk
Priority to PL99345038A priority patent/PL345038A1/xx
Priority to IL13973899A priority patent/IL139738A/en
Priority to BR9911423-2A priority patent/BR9911423A/pt
Priority to AU45195/99A priority patent/AU744801B2/en
Priority to JP2000555856A priority patent/JP2002518470A/ja
Priority to AT99928068T priority patent/ATE269296T1/de
Priority to APAP/P/2000/002001A priority patent/AP2000002001A0/en
Priority to EP99928068A priority patent/EP1089963B1/fr
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to KR1020007014549A priority patent/KR20010053076A/ko
Priority to CA002335513A priority patent/CA2335513A1/fr
Priority to EA200100065A priority patent/EA200100065A1/ru
Priority to HU0102776A priority patent/HUP0102776A3/hu
Priority to SI9930648T priority patent/SI1089963T1/xx
Priority to DE69918113T priority patent/DE69918113T2/de
Publication of WO1999067201A1 publication Critical patent/WO1999067201A1/fr
Priority to NO20006349A priority patent/NO20006349L/no
Priority to BG105154A priority patent/BG105154A/bg
Priority to HK01106515A priority patent/HK1025894A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • This invention relates to novel inhibitors of the formation of soluble human CD23 and their use in the treatment of conditions associated with excess production of soluble CD23 (s-CD23) such as autoimmune disease and allergy.
  • the compounds of the invention are also inhibitors of the release of tumour necrosis factor (TNF).
  • CD23 (the low affinity IgE receptor FceRJI, Blast 2), is a 45 kDa type II integral protein expressed on the surface of a variety of mature cells, including B and T lymphocytes, macrophages, natural killer cells, Langerhans cells, monocytes and platelets (Delespesse et al, Adv Immunol, 49 [1991] 149-191). There is also a CD23-like molecule on eosinophils (Grangette et al, J Immunol, 143 [1989] 3580-3588). CD23 has been implicated in the regulation of the immune response (Delespesse et al, Immunol Rev, _T25 [1992] 77-97).
  • Human CD23 exists as two differentially regulated isoforms, a and b, which differ only in the amino acids at the intracellular N-terminus (Yokota et al, Cell, 55 [1988] 611- 618). In man the constitutive a isoform is found only on B-lymphocytes, whereas type b, inducible by IL4, is found on all cells capable of expressing CD23.
  • i-CD23 cell bound CD23
  • s-CD23 well-defined soluble fragments
  • S-CD23 has been implicated in the ove ⁇ roduction of IgE, the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjuctivitis, eczema, atopic dermatitis and anaphylaxis (Sutton and Gould, Nature, 366, [1993] 421-428).
  • Other biological activities attributed to S-CD23 include the stimulation of B cell growth and the induction of the release of mediators from monocytes.
  • s- CD23 has been observed in the serum of patients having B-chronic lymphocytic leukaemia (Sarfati et al, Blood, 71 [1988] 94-98) and in the synovial fluids of patients with rheumatoid arthritis (Chomarat et al, Arthritis and Rheumatism, 36 [1993] 234-242). That there is a role for CD23 in inflammation is suggested by a number of sources. First, sCD23 has been reported to bind to extracellular receptors which when activated are involved in cell-mediated events of inflammation.
  • sCD23 is reported to directly activate monocyte TNF, IL-1, and IL-6 release (Armant et al, vol 180, J.Exp. Med., 1005-101 1 (1994)).
  • CD23 has been reported to interact with the B2-integrin adhesion molecules, CD1 lb and CD1 lc on monocyte/macrophage (S. Lecoanet-Henchoz et al, Immunity, vol 3; 119-125 (1995)) which trigger NO2" , hydrogen peroxide and cytokine ( IL-1, IL-6, and TNF) release.
  • IL-4 or IFN induce the expression of CD23 and its release as sCD23 by human monocytes.
  • compounds which inhibit the formation of S-CD23 should have twofold actions of a) enhancing negative feedback inhibition of IgE synthesis by maintaining levels of i-CD23 on the surface of B cells, and b) inhibiting the immunostimulatory cytokine activities of higher molecular weight soluble fragments (Mr 37, 33 and 29 kDa) of S-CD23.
  • inhibition of CD23 cleavage should mitigate sCD23-induced monocyte activation and mediator formation, thereby reducing the inflammatory response.
  • TNF ⁇ is a pro-inflammatory cytokine which is released from stimulated cells by specific cleavage of a 76-amino acid signal sequence in the inactive precursor to generate the mature form.
  • TNF ⁇ The cleavage of TNF ⁇ has been reported to be carried out by a metalloprotease (Gearing, A.J.H. et al, (1994) Nature 370, 555-557; McGeehan, G.M. et al, (1994) Nature 370, 558-561; Mohler, K.M. et al, (1994) Nature 370, 218-220).
  • Compounds reported to inhibit the cleavage of TNF ⁇ by the TNF processing enzyme can be broadly described as matrix metalloprotease inhibitors, particularly of the hydroxamic acid class. .
  • TNF ⁇ is induced in a variety of cell types in response to bacteria, endotoxin, various viruses and parasites, so that one physiological function ascribed to TNF ⁇ is a contribution to the inflammatory response to acute infection by bacteria, parasites, etc (Dinarello, CA. (1992) Immunol. 4, 133-145).
  • Overproduction of TNF ⁇ has been implicated in disease states such as rheumatoid arthritis, septic shock, Crohn's disease and cachexia (Dinarello, 1992). Inhibition of processing of TNF ⁇ to the mature, active form would therefore be beneficial in the treatment of these inflammatory disorders.
  • TNF ⁇ may also contribute to the destruction of tissue in autoimmune disease although it is not a initiating factor in these diseases.
  • TNF ⁇ antibodies have been shown to reduce the severity of disease in short term studies in rheumatoid arthritis models (Elliott, M.J., et al (1993) Arthrit. Rheum. 12, 1681-1690; Elliott et al (1994) Lancet 344, 1125-1127).
  • WO 96/02240 discloses that compounds which inhibit the action of matrix metalloproteases (eg collagenase, stromelysin and gelatinase) are effective inhibitors of the release of human soluble CD23 transfected into mammalian cell culture systems.
  • matrix metalloproteases eg collagenase, stromelysin and gelatinase
  • UK Patent Application No. 9601041.8 discloses that certain compounds of formula (I) are effective inhibitors of the release of human soluble CD23 transfected into mammalian cell culture systems:
  • R is methyl substituted by one to three groups selected from alkyl, aryl, alkenyl, and alkynyl;
  • R! is arylmethyl or heterocyclylmethyl
  • R2 is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl
  • R3 is hydrogen, alkyl, alkenyl, alkynyl or aryl.
  • Alkyl, alkenyl and alkynyl groups referred to herein include straight and branched groups containing up to six carbon atoms and are optionally substimted by one or more groups selected from the group consisting of aryl, heterocyclyl, (C ⁇ _6)alkylthio, (C ⁇ _g)alkoxy, aryl(Ci.g)alkoxy, aryl(C 6)alkylthio, amino, mono- or di-(C ⁇ _6)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy, and halogen.
  • Cycloalkyl and cycloalkenyl groups referred to herein include groups having between three and eight ring carbon atoms and are optionally substituted as described hereinabove for alkyl, alkenyl and alkynyl groups.
  • aryl means single and fused rings suitably containing from 4 to 7, preferably 5 or 6, ring atoms in each ring, which rings, may each be unsubstituted or substimted by, for example, up to three substituents.
  • a fused ring system may include aliphatic rings and need include only one aromatic ring.
  • Suitable aryl groups include phenyl and naphthyl such as 1 -naphthyl or 2- naphthyl.
  • any aryl group, including phenyl and naphthyl may be optionally substituted by up to five, preferably up to three substituents.
  • Suitable substituents include halogen, (C ⁇ _6)alkyl, aryl, aryl(C i _6)alkyl, (C ⁇ _6)alkoxy,
  • heterocyclyl and “heterocyclic” suitably include, unless otherwise defined, aromatic and non-aromatic, single and fused, rings suitably containing up to four heteroatoms in each ring, each of which is selected from oxygen, nitrogen and sulphur, which rings, may be unsubstituted or substituted by, for example, up to three substituents.
  • Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms.
  • a fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.
  • a substituent for a heterocyclyl group is selected from halogen,
  • R is allyl, propyl, ethyl or isopropyl, and/or R ⁇ is 1- or 2-naphthylmethyl; and/or R ⁇ is t-butyl; and/or R J is hydrogen or methyl.
  • each of R to R J is selected from the group consisting of the values ascribed to it in the Examples hereinbelow.
  • the compound of formula (I) of the invention is selected from the group consisting of the compounds described in the Examples hereinbelow.
  • the present invention provides the use of a compound of formula (I) for the production of a medicament for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the ove ⁇ roduction of S-CD23 is implicated.
  • the invention provides a method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the ove ⁇ roduction of S-CD23 is implicated, which method comprises the administration of a compound of formula (I), to a human or non- human mammal in need thereof.
  • the invention also provides a pharmaceutical composition for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the ove ⁇ roduction of S-CD23 is implicated which comprises a compound of formula (I) and optionally a pharmaceutically acceptable carrier therefor.
  • the present invention provides the use of a compound of formula (I) for the production of a ' medicament for the treatment or prophylaxis of conditions mediated by TNF, including, but not limited to, inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia and anorexia, acute infections, shock states, graft versus host reactions and autoimmune disease.
  • the invention provides a method for the treatment or prophylaxis of conditions mediated by TNF, which method comprises the administration of a compound of formula (I), to a human or non-human mammal in need thereof.
  • the invention also provides a pharmaceutical composition for the treatment or prophylaxis of conditions mediated by TNF, which comprises a compound of formula (I) and optionally a pharmaceutically acceptable carrier therefor.
  • a pharmaceutical composition for the treatment or prophylaxis of conditions mediated by TNF which comprises a compound of formula (I) and optionally a pharmaceutically acceptable carrier therefor.
  • Particular inflammatory disorders include CNS disorders such as
  • Alzheimers disease multiple sclerosis, and multi-infarct dementia, as well as the inflammation mediated sequelae of stroke and head trauma.
  • Salts of compounds of formula (I) include for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, hydroiodides, p-toluenesulphonates, phosphates, sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartarates and benzoates.
  • inorganic or organic acids such as hydrochlorides, hydrobromides, hydroiodides, p-toluenesulphonates, phosphates, sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartarates and benzoates.
  • Salts may also be formed with bases.
  • Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as sodium or potassium salts, and organic amine salts such as mo ⁇ holine, piperidine, dimethylamine or diethylamine salts.
  • the compounds ofthe present invention are potent and selective inhibitors of CD23 processing and TNF release, whilst exhibiting reduced collagenase inhibitory activity in comparison with the above- mentioned compounds ofthe prior art.
  • the compounds of the invention also exhibit advantageous in-vivo abso ⁇ tion properties via the oral route.
  • a further aspect ofthe invention provides a process for preparing a compound of formula (I) as defined hereinabove, which process comprises: (a) deprotecting a compound of formula (II):
  • n and R to R ⁇ are as defined hereinabove, and X is a protecting group such as benzyl or trimethylsilyl or
  • n and R to R ⁇ are as defined hereinabove, and any hydroxy group is optionally protected, with hydroxylamine or a salt thereof, or
  • Compounds of formula (II) can be prepared from compounds of formula (III) by reaction with a protected hydroxylamine.
  • Compounds of formula (III) having one or more protected hydroxy groups can be converted by hydrolysis to a corresponding unprotected compound of formula (III).
  • Suitable protecting groups for a hydroxamic acid are well known in the art and include benzyl, trimethylsilyl, t-butyl and t-butyldimethylsilyl.
  • Suitable protecting groups for a carboxylic acid are well known in the art and include t-butyl , benzyl and methyl.
  • Compounds of formula (VI) wherein Z is hydrogen can be prepared by reacting a diester (such as the dimethyl or diethyl ester) of 2-hydroxy succinic acid with a compound of formula R ⁇ ' in the presence of a strong base such as lithium diisopropylamide, wherein X' is a leaving group such as bromine or iodine, and then hydrolysing the resulting compound to remove the ester groups.
  • a diester such as the dimethyl or diethyl ester
  • R ⁇ ' in the presence of a strong base such as lithium diisopropylamide, wherein X' is a leaving group such as bromine or iodine
  • the isomers, including stereoisomers, ofthe compounds ofthe present invention may be prepared as mixtures of such isomers or as individual isomers.
  • the individual isomers may be prepared by any appropriate method, for example individual stereoisomers may be prepared by stereospecific chemical synthesis starting from chiral substrates or by separating mixtures of diastereoisomers using known methods.
  • the invention provides compounds of formula (IA):
  • the compounds are isolated in substantially pure form.
  • an inhibitor ofthe formation of soluble human CD23 has useful medical properties.
  • the active compounds are administered as pharmaceutically acceptable compositions.
  • compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example in the form of a spray, aerosol or other conventional method for inhalation, for treating respiratory tract disorders; or parenteral administration for patients suffering from heart failure. Other alternative modes of administration include sublingual or transdermal administration.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions. In order to obtain consistency of administration it is preferred that a composition ofthe invention is in the form of a unit dose.
  • Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
  • the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • Oral liquid preparations may be in the form of. for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose,
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and. depending on the concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution ofthe compound.
  • compositions of this invention may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose.
  • the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns for example diameters in the range of 1-50 microns, 1-10 microns or 1-5 microns.
  • compositions may contain from 0.1 % to 99% by weight, preferably from 10-60% by weight, ofthe active material, depending upon the method of administration.
  • a preferred range for inhaled administration is 10-99%, especially 60-99%, for example 90, 95 or 99%.
  • Microfine powder formulations may suitably be administered in an aerosol as a metered dose or by means of a suitable breath-activated device.
  • Suitable metered dose aerosol formulations comprise conventional propellants, cosolvents, such as ethanol, surfactants such as oleyl alcohol, lubricants such as oleyl alcohol, desiccants such as calcium sulphate and density modifiers such as sodium chloride.
  • Suitable solutions for a nebulizer are isotonic sterilised solutions, optionally buffered, at for example between pH 4-7, containing up to 20mg/ml of compound but more generally 0.1 to lOmg/ml, for use with standard nebulisation equipment.
  • a unit dose form of a composition ofthe invention may contain from 0.1 to lOOOmg of a compound ofthe invention (0.001 to lOmg via inhalation) and more usually from 1 to 500mg, for example 1 to 25 or 5 to 500mg.
  • Such compositions may be administered from 1 to 6 times a day, more usually from 2 to 4 times a day, in a manner such that the daily dose is from lmg to lg for a 70 kg human adult and more particularly from 5 to 500mg. That is in the range of about 1.4 x 10"2 mg/kg/day to 14 mg/kg/day and more particularly in the range of about 7 x 10"2 mg/kg/day to 7 mg/kg/day.
  • Procedure 1 The ability of test compounds to inhibit the release of soluble CD23 was investigated by use ofthe following procedure.
  • Plasma membranes from RPMI 8866 cells, a human Epstein-Barr virus transformed B-cell line (Sarfati et al., Immunology 60 [1987] 539-547) expressing high levels of CD23 are purified using an aqueous extraction method.
  • Cells resuspended in homogenization buffer (20mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgC12, 1 mM DTT) are broken by N2 cavitation in a Parr bomb and the plasma membrane fraction mixed with other membranes is recovered by centrifugation at 10,000Xg.
  • the light pellet is resuspended in 0.2 M potassium phosphate, pH 7.2 using 2 ml per 1 -3 g wet cells and the nuclear pellet is discarded.
  • the membranes are further fractionated by partitioning between Dextran 500 (6.4% w/w) and polyethylene glycol (PEG) 5000 (6.4% w/w) (ref), at 0.25 M sucrose in a total of 16 g per 10-15 mg membrane proteins [Morre and Morre, BioTechniques 7, 946-957 (1989)].
  • the phases are separated by brief centrifugation at lOOOXg and the PEG (upper) phase is collected, diluted 3-5 fold with 20 mM potassium phosphate buffer pH 7.4, and centrifuged at 100,000Xg to recover membranes in that phase.
  • the pellet is resuspended in phosphate- buffered saline and consists of 3-4 fold enriched plasma membranes as well as some other cell membranes (e.g. lysosomes, Golgi).
  • the membranes are aliquoted and stored at -80°C. Fractionation at 6.6 % Dextran/PEG yields plasma membranes enriched 10-fold.
  • the fractionated membranes are incubated at 37°C for times up to 4 hrs to produce fragments of CD23 which are separated from the membrane by filtration in 0.2 micron Durapore filter plates (Millipore) after quenching the assay with 5 uM Preparation 1 from P 30994.
  • sCD23 released from the membrane is determined using the EIA kit from The Binding Site (Birmingham, UK) or a similar one utilizing MHM6 anti-CD23 mAb [Rowe et al., Int. J. Cancer, 29, 373- 382 (1982)] or another anti-CD23 mAb as the capture antibody in a sandwich EIA..
  • the amount of soluble CD23 made by 0.5 ug membrane protein in a total volume of 50 ul phosphate-buffered saline is measured by EIA and compared to the amount made in the presence of various concentrations of inhibitors.
  • Inhibitors are prepared in solutions of water or dimethylsulfoxide (DMSO) and the final DMSO concentration is not more than 2 %.
  • IC50's are determined by curve fitting as the concentration where 50 % inhibition of production of sCD23 is observed relative to the difference in sCD23 between controls incubated without inhibitor.
  • Procedure 2 The ability of test compounds to inhibit collagenase was investigated using the following procedure.
  • the potency of compounds to act as inhibitors of collagenase was determined by the method of Cawston and Barrett (Anal. Biochem. 99, 340-345, 1979), hereby inco ⁇ orated by reference, whereby a 1 mM solution ofthe inhibitor being tested or dilutions thereof, was incubated at 37 °C for 18 h with collagen and human recombinant collagenase, from synovial fibroblasts cloned, expressed and purified from E. Coli, (buffered with 150 mM Tris, pH 7.6, containing 15 mM calcium chloride, 0.05% Brij 35, 200 mM sodium chloride and 0.02% sodium azide).
  • the collagen was acetylated ⁇ H type 1 bovine collagen prepared by the method of Cawston and Mu ⁇ hy (methods in Enzymology 80, 711,1981) The samples were centrifuged to sediment undigested collagen and an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of ImM inhibitor, or dilution thereof, was compared to activity in a control devoid of inhibitor and the results reported as that concentration effecting 50% ofthe collagenase (IC50).
  • Procedure 3 The ability of test compounds to inhibit TNF release was investigated using the following procedure. Assay for inhibition of release of TNF ⁇ from human monocytes stimulated by lipopolysaccharide (LPS) endotoxin.
  • LPS lipopolysaccharide
  • % fetal calf serum are centrifuged at lOOOXg for 5 min and then resuspended in medium at 2 X 10 6 cells/ ml.
  • the cell suspension is aliquoted in 24 well plates, 1 ml per well.
  • Compounds to be tested are dissolved in neat dimethyl sulfoxide (DMSO) and added to culture with the final DMSO concentration at 0.1 %.
  • Compounds are added to cells in triplicate wells. TNF ⁇ release is stimulated by addition of LPS to the cells at a final concentration of 200 ng/ml. Appropriate control cultures are set up in triplicates also.
  • DMSO dimethyl sulfoxide
  • the plates are incubated for 18-20 hrs at 37° C, 5% CO 2 , then centrifuged at 1000 Xg for 5 min.
  • a specific ELISA for human TNF ⁇ (SmithKline Beecham) is used to measure TNF levels in the cell-free culture supernatants.
  • 6-Fluoro-2-methylnaphthalene (20.5 g, 128 mmol, prepared by adaptation ofthe method of Wolinska-Mocydlarz et al 2 ) and NBS (22.8 g, 128 mmol) were heated at reflux for 16 hr in CCI4 (210 mL) during which time, benzoyl peroxide (2.5 g) was added portionwise. The cooled solution was filtered and evaporated and the residue was extracted thoroughly with hexane (4 x 250 mL). The extracts were decanted from tarry material, combined and evaporated to give the product as a yellow solid, 29.8 g (97 %).
  • N-[3S-(AUyloxy)- 4-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert- leucinamide can also be prepared from (3R-Naphthylmethyl)-2S-hydroxy succinic acid diethyl ester as follows:-
  • 3S-Allyloxy-2R- naphthylmethylsuccinic acid diethyl ester can be hydrolysed, treated with trifluoroacetic anhydride then methanol, coupled to (S)-tert-leucinamide and hydrolysed to give N-[3S-(AIlyloxy)- 4-hydroxy-2R-(2- naphthylmethyl)succinyl]-S-tert-leucinamide.
  • N'-[3S,4-Dihydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (1.5 g, 3.75 mmol) in DMF (25 mL), was treated with HOBT (1.15 g, 7.51 mmol), and DEC (1.44 g, 7.51 mmol). After stirring the mixture for 20 min., O- benzylhydroxylamine (0.92 mL), was added. The reaction was stirred at room temp, for 6 hr., and the DMF was then removed in vacuo. To the residue was added NaHCO3 soln. and the mixture was extracted (2X) with EtOAc.
  • the mesylate (660mg) was stirred in ethanol (6ml) with dimethylamine (3ml) in a sealed vessel for 20 hrs. The solvents were evaporated and ethyl acetate and saturated sodium carbonate solution were added and the product was extracted into ethyl acetate. The extracts were washed with brine, dried (Na2SO4) and evaporated. Filtration through a short column of silica gel (elution with dichloromethane/methanol) gave a white foam (520mg, 86%).
  • the title product was prepared as previously described (e.g. Example 80) and crystallised from Et2 ⁇ /EtOAc/MeOH, to give a cream solid, 0.276 g (76 %).
  • Example 65 alkylating N-[4-t- Butoxy-3 S-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine benzyl ester with ⁇ rOTf) and triturating the final compound with Et2 ⁇ /EtOAc), to give a cream solid, 0.32 lg (69 %).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Les composés correspondant à la formule (I), formule dans laquelle R représente un méthyle substitué par un à trois groupes sélectionnés dans le groupe constitué par un alkyle, un aryle, un alcényle et un alcynyle, la valeur de n étant 0 ou 1, R1 représentant un aryl-méthyle ou un hétérocyclylméthyle, R2 représentant un alkyle, un alcényle, un aryle, un cycloalkyle ou un cycloalcényle et R3 représentant un hydrogène, un alkyle, un alcényle un alcynyle ou un aryle, s'avèrent des plus utiles s'agissant de traiter des troubles provoqués par la protéine s-CD23.
PCT/GB1999/001954 1998-06-22 1999-06-22 Derives d'acide hydroxamique comme inhibiteurs de la production de la proteine humaine cd23 et de la liberation du facteur de necrose des tumeurs (tnf) WO1999067201A1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
EP99928068A EP1089963B1 (fr) 1998-06-22 1999-06-22 Derives d'acide hydroxamique comme inhibiteurs de la production de la proteine humaine cd23 et de la liberation du facteur de necrose des tumeurs (tnf)
SK1956-2000A SK19562000A3 (sk) 1998-06-22 1999-06-22 Deriváty kyseliny hydroxámovej, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
PL99345038A PL345038A1 (en) 1998-06-22 1999-06-22 Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release
IL13973899A IL139738A (en) 1998-06-22 1999-06-22 Derivatives of hydroxamic acid as inhibitors of human CD23 production and TNF release
BR9911423-2A BR9911423A (pt) 1998-06-22 1999-06-22 Derivados do ácido hidroxâmico como inibidores da produção de cd23 humano e da liberação de tnf
AU45195/99A AU744801B2 (en) 1998-06-22 1999-06-22 Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release
JP2000555856A JP2002518470A (ja) 1998-06-22 1999-06-22 ヒトｃｄ２３の産生およびその放出の阻害剤としてのヒドロキサム酸誘導体
AT99928068T ATE269296T1 (de) 1998-06-22 1999-06-22 Hydroxamsäure-derivate als inhibitoren der produktion von menschlichen cd23 und der freigabe von tnf
KR1020007014549A KR20010053076A (ko) 1998-06-22 1999-06-22 인간 ｃｄ23의 생산 및 ｔｎｆ 방출에 대한 억제제로서의히드록스암산 유도체
NZ508229A NZ508229A (en) 1998-06-22 1999-06-22 Hydroxamic acid derivatives as inhibitors of the production of human soluble CD23 and the TNF release for treating autoimmune diseases or allergies
US09/701,946 US6458779B1 (en) 1998-06-22 1999-06-22 Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release
APAP/P/2000/002001A AP2000002001A0 (en) 1998-06-22 1999-06-22 Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the tnf relaease.
CA002335513A CA2335513A1 (fr) 1998-06-22 1999-06-22 Derives d'acide hydroxamique comme inhibiteurs de la production de la proteine humaine cd23 et de la liberation du facteur de necrose des tumeurs (tnf)
EA200100065A EA200100065A1 (ru) 1998-06-22 1999-06-22 Производные гидроксамовой кислоты как ингибиторы продуцирования cd23 человека и высвобождения tnf
HU0102776A HUP0102776A3 (en) 1998-06-22 1999-06-22 Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release
SI9930648T SI1089963T1 (en) 1998-06-22 1999-06-22 Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release
DE69918113T DE69918113T2 (de) 1998-06-22 1999-06-22 Hydroxamsäurederivate als Inhibitoren der Herstellung von menschlichem CD23 und der TNF-Freisetzung
NO20006349A NO20006349L (no) 1998-06-22 2000-12-13 Hydroksamsyrederivater som inhibitorer for produksjon av humant CD23 og av TNF-frigjöring
BG105154A BG105154A (bg) 1998-06-22 2001-01-15 Производни на хидроксамова киселина като инхибитори за получаване на човешки cd23 и отделяне на tnf
HK01106515A HK1025894A1 (en) 1998-06-22 2001-09-14 Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9813451.3A GB9813451D0 (en) 1998-06-22 1998-06-22 Novel compounds
GB9813451.3 1998-06-22

Publications (1)

Publication Number Publication Date
WO1999067201A1 true WO1999067201A1 (fr) 1999-12-29

Family

ID=10834177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001954 WO1999067201A1 (fr) 1998-06-22 1999-06-22 Derives d'acide hydroxamique comme inhibiteurs de la production de la proteine humaine cd23 et de la liberation du facteur de necrose des tumeurs (tnf)

Country Status (32)

Country Link
US (1) US6458779B1 (fr)
EP (1) EP1089963B1 (fr)
JP (1) JP2002518470A (fr)
KR (1) KR20010053076A (fr)
CN (1) CN1306508A (fr)
AP (1) AP2000002001A0 (fr)
AR (1) AR029303A1 (fr)
AT (1) ATE269296T1 (fr)
AU (1) AU744801B2 (fr)
BG (1) BG105154A (fr)
BR (1) BR9911423A (fr)
CA (1) CA2335513A1 (fr)
DE (1) DE69918113T2 (fr)
DK (1) DK1089963T3 (fr)
EA (1) EA200100065A1 (fr)
ES (1) ES2222711T3 (fr)
GB (1) GB9813451D0 (fr)
HK (1) HK1025894A1 (fr)
HU (1) HUP0102776A3 (fr)
ID (1) ID27413A (fr)
IL (1) IL139738A (fr)
MY (1) MY121785A (fr)
NO (1) NO20006349L (fr)
NZ (1) NZ508229A (fr)
OA (1) OA11639A (fr)
PL (1) PL345038A1 (fr)
PT (1) PT1089963E (fr)
SI (1) SI1089963T1 (fr)
SK (1) SK19562000A3 (fr)
TR (1) TR200003877T2 (fr)
WO (1) WO1999067201A1 (fr)
ZA (1) ZA200007254B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030747A1 (fr) * 1999-10-27 2001-05-03 Smithkline Beecham P.L.C. Derive d'acide hydroxamique en tant qu'inhibiteur de formation du cd23 soluble humain
WO2001044221A1 (fr) * 1999-12-14 2001-06-21 Smithkline Beecham Plc Derives d'acide hydroxamique en tant qu'inhibiteurs du cd23 humain et de la liberation du facteur de necrose des tumeurs (tnf)
WO2001062715A1 (fr) * 2000-02-24 2001-08-30 Smithkline Beecham P.L.C. Nouveaux inhibiteurs de la cd23
WO2004076386A2 (fr) 2003-02-25 2004-09-10 Topotarget Uk Limited Composes d'acide carbamique comprenant un groupe heteroaryle bicyclique utilises en tant qu'inhibiteurs de hdac

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082200A1 (en) * 1994-07-13 2002-06-27 Smithkline Beecham P.1.C. Use of inhibitors of human S-CD23
US6716878B1 (en) * 1999-04-09 2004-04-06 Vernalis (Oxford) Limited Antimicrobial agents

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010990A1 (fr) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition de la production du facteur de necrose tumorale
WO1996002240A2 (fr) * 1994-07-13 1996-02-01 Smithkline Beecham P.L.C. Utilisation d'inhibiteurs de s-cd23 humaine
WO1996033166A1 (fr) * 1995-04-18 1996-10-24 The Du Pont Merck Pharmaceutical Company Acides hydrodynamiques et carboxyliques inhibiteurs des metalloproteases
WO1996033165A1 (fr) * 1995-04-18 1996-10-24 British Biotech Pharmaceuticals Limited Derives de succinamide et leur utilisation en tant qu'inhibiteurs de la metalloproteinase
WO1997002239A1 (fr) * 1995-06-30 1997-01-23 British Biotech Pharmaceuticals Limited Inhibiteurs de metalloproteinases matricielles
WO1997015553A1 (fr) * 1995-10-23 1997-05-01 Sankyo Company, Limited Derives de l'acide hydroxamique
WO1998043959A1 (fr) * 1997-03-28 1998-10-08 Zeneca Limited Acides hydroxamiques substitues par des composes heterocycliques pouvant inhiber le facteur de necrose tumorale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609794D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010990A1 (fr) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition de la production du facteur de necrose tumorale
WO1996002240A2 (fr) * 1994-07-13 1996-02-01 Smithkline Beecham P.L.C. Utilisation d'inhibiteurs de s-cd23 humaine
WO1996033166A1 (fr) * 1995-04-18 1996-10-24 The Du Pont Merck Pharmaceutical Company Acides hydrodynamiques et carboxyliques inhibiteurs des metalloproteases
WO1996033165A1 (fr) * 1995-04-18 1996-10-24 British Biotech Pharmaceuticals Limited Derives de succinamide et leur utilisation en tant qu'inhibiteurs de la metalloproteinase
WO1997002239A1 (fr) * 1995-06-30 1997-01-23 British Biotech Pharmaceuticals Limited Inhibiteurs de metalloproteinases matricielles
WO1997015553A1 (fr) * 1995-10-23 1997-05-01 Sankyo Company, Limited Derives de l'acide hydroxamique
WO1998043959A1 (fr) * 1997-03-28 1998-10-08 Zeneca Limited Acides hydroxamiques substitues par des composes heterocycliques pouvant inhiber le facteur de necrose tumorale

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030747A1 (fr) * 1999-10-27 2001-05-03 Smithkline Beecham P.L.C. Derive d'acide hydroxamique en tant qu'inhibiteur de formation du cd23 soluble humain
AU766072B2 (en) * 1999-10-27 2003-10-09 Smithkline Beecham Plc Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
US6673965B1 (en) * 1999-10-27 2004-01-06 Smithkline Beecham P.L.C. Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
WO2001044221A1 (fr) * 1999-12-14 2001-06-21 Smithkline Beecham Plc Derives d'acide hydroxamique en tant qu'inhibiteurs du cd23 humain et de la liberation du facteur de necrose des tumeurs (tnf)
WO2001062715A1 (fr) * 2000-02-24 2001-08-30 Smithkline Beecham P.L.C. Nouveaux inhibiteurs de la cd23
WO2004076386A2 (fr) 2003-02-25 2004-09-10 Topotarget Uk Limited Composes d'acide carbamique comprenant un groupe heteroaryle bicyclique utilises en tant qu'inhibiteurs de hdac
WO2004076386A3 (fr) * 2003-02-25 2004-10-28 Topotarget Uk Ltd Composes d'acide carbamique comprenant un groupe heteroaryle bicyclique utilises en tant qu'inhibiteurs de hdac
JP2006518730A (ja) * 2003-02-25 2006-08-17 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むカルバミン酸化合物
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
AU2004215624B2 (en) * 2003-02-25 2011-06-02 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
JP4790594B2 (ja) * 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
US8071620B2 (en) 2003-02-25 2011-12-06 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors

Also Published As

Publication number Publication date
JP2002518470A (ja) 2002-06-25
NZ508229A (en) 2003-12-19
CA2335513A1 (fr) 1999-12-29
IL139738A (en) 2005-12-18
HK1025894A1 (en) 2000-12-01
OA11639A (en) 2004-11-27
TR200003877T2 (tr) 2001-06-21
PL345038A1 (en) 2001-11-19
EA200100065A1 (ru) 2001-06-25
AP2000002001A0 (en) 2000-12-31
ES2222711T3 (es) 2005-02-01
BR9911423A (pt) 2001-03-13
HUP0102776A3 (en) 2002-11-28
NO20006349D0 (no) 2000-12-13
SI1089963T1 (en) 2004-12-31
CN1306508A (zh) 2001-08-01
GB9813451D0 (en) 1998-08-19
BG105154A (bg) 2001-08-31
ZA200007254B (en) 2002-02-07
DE69918113D1 (de) 2004-07-22
AU744801B2 (en) 2002-03-07
DE69918113T2 (de) 2005-07-07
AR029303A1 (es) 2003-06-25
SK19562000A3 (sk) 2001-08-06
AU4519599A (en) 2000-01-10
HUP0102776A2 (hu) 2001-12-28
EP1089963A1 (fr) 2001-04-11
NO20006349L (no) 2000-12-13
ID27413A (id) 2001-04-05
DK1089963T3 (da) 2004-10-18
IL139738A0 (en) 2002-02-10
KR20010053076A (ko) 2001-06-25
PT1089963E (pt) 2004-10-29
US6458779B1 (en) 2002-10-01
EP1089963B1 (fr) 2004-06-16
MY121785A (en) 2006-02-28
ATE269296T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
US6235753B1 (en) Inhibitors of the production of S-CD23 and the secretion of TNF
EP1089963B1 (fr) Derives d'acide hydroxamique comme inhibiteurs de la production de la proteine humaine cd23 et de la liberation du facteur de necrose des tumeurs (tnf)
EP1448552B1 (fr) Derives quinoleique, procede de preparation et utilisation de ceux-ci dans le traitement de maladies induites par s-cd23
WO2001085721A1 (fr) Derives d'acide n-sulfonique hydroxamique en tant qu'inhibiteurs de cd23
AU725056B2 (en) Hydroxamic acid based collagenase inhibitors
US20060247271A1 (en) Sulphonyl hydroxamic acid derivatives as inhibitors of s-cd23
WO1997043250A1 (fr) Composes a base d'acide hydroxamique, inhibiteurs de la formation de cd23 et de facteur de necrose des tumeurs
CA2410294A1 (fr) N-hydroxyformamides a substitution bicyclyle ou heterobicyclylmethanesulfonylamino
MXPA00012854A (en) Hydroxamic acid derivatives as inhibitors of the production of human cd23 and ofthe tnf release
EP1448529B1 (fr) Derives de sulfone appropries au traitement des maladies auto-immunitaires et des allergies
CZ20004818A3 (cs) Deriváty kyseliny hydroxamové jako inhibitory produkce lidské CD23 a uvolňování TNF
US20040209822A1 (en) Novel compounds
WO2001044221A1 (fr) Derives d'acide hydroxamique en tant qu'inhibiteurs du cd23 humain et de la liberation du facteur de necrose des tumeurs (tnf)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99807653.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 139738

Country of ref document: IL

Ref document number: 508229

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/00671/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999928068

Country of ref document: EP

Ref document number: 45195/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000/07254

Country of ref document: ZA

Ref document number: 200007254

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2335513

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012854

Country of ref document: MX

Ref document number: 19562000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2000-4818

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007014549

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000/03877

Country of ref document: TR

Ref document number: 1200001184

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 1999 105154

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200100065

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09701946

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999928068

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007014549

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-4818

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 45195/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999928068

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007014549

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载